Research ArticleArticle
Pharmacological Inhibition and Genetic Knockdown of Exchange Protein Directly Activated by cAMP 1 Reduce Pancreatic Cancer Metastasis In Vivo
Muayad Almahariq, Celia Chao, Fang C. Mei, Mark R. Hellmich, Igor Patrikeev, Massoud Motamedi and Xiaodong Cheng
Molecular Pharmacology February 2015, 87 (2) 142-149; DOI: https://doi.org/10.1124/mol.114.095158
Muayad Almahariq
Department of Integrative Biology and Pharmacology, Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas (M.A., F.C.M., X.C.); and Departments of Pharmacology and Toxicology (M.A.), Surgery (M.R.H., C.C.), and Ophthalmology and Visual Sciences (I.P., M.M.), University of Texas Medical Branch, Galveston, Texas
Celia Chao
Department of Integrative Biology and Pharmacology, Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas (M.A., F.C.M., X.C.); and Departments of Pharmacology and Toxicology (M.A.), Surgery (M.R.H., C.C.), and Ophthalmology and Visual Sciences (I.P., M.M.), University of Texas Medical Branch, Galveston, Texas
Fang C. Mei
Department of Integrative Biology and Pharmacology, Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas (M.A., F.C.M., X.C.); and Departments of Pharmacology and Toxicology (M.A.), Surgery (M.R.H., C.C.), and Ophthalmology and Visual Sciences (I.P., M.M.), University of Texas Medical Branch, Galveston, Texas
Mark R. Hellmich
Department of Integrative Biology and Pharmacology, Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas (M.A., F.C.M., X.C.); and Departments of Pharmacology and Toxicology (M.A.), Surgery (M.R.H., C.C.), and Ophthalmology and Visual Sciences (I.P., M.M.), University of Texas Medical Branch, Galveston, Texas
Igor Patrikeev
Department of Integrative Biology and Pharmacology, Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas (M.A., F.C.M., X.C.); and Departments of Pharmacology and Toxicology (M.A.), Surgery (M.R.H., C.C.), and Ophthalmology and Visual Sciences (I.P., M.M.), University of Texas Medical Branch, Galveston, Texas
Massoud Motamedi
Department of Integrative Biology and Pharmacology, Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas (M.A., F.C.M., X.C.); and Departments of Pharmacology and Toxicology (M.A.), Surgery (M.R.H., C.C.), and Ophthalmology and Visual Sciences (I.P., M.M.), University of Texas Medical Branch, Galveston, Texas
Xiaodong Cheng
Department of Integrative Biology and Pharmacology, Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas (M.A., F.C.M., X.C.); and Departments of Pharmacology and Toxicology (M.A.), Surgery (M.R.H., C.C.), and Ophthalmology and Visual Sciences (I.P., M.M.), University of Texas Medical Branch, Galveston, Texas
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Inhibition of EPAC1 Reduces PDA Metastasis
Muayad Almahariq, Celia Chao, Fang C. Mei, Mark R. Hellmich, Igor Patrikeev, Massoud Motamedi and Xiaodong Cheng
Molecular Pharmacology February 1, 2015, 87 (2) 142-149; DOI: https://doi.org/10.1124/mol.114.095158
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement